A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Trial Profile

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2013

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2010 According to a LEO Pharma media release, results from this trial were presented in a poster at the 68th Annual Meeting of the American Academy of Dermatology.
    • 14 Aug 2008 The expected completion date for this trial is now 31 Mar 2009, according to Peplin.
    • 14 Aug 2008 Pelin expects to announce results from this trial early in quarter 1 of 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top